HEME Home Transfusion Program

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Dana-Farber Cancer Institute
Study ID
NCT06487247
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • HEME-Hospice Program — BEHAVIORAL
    A care delivery program that combines home-based transfusions with routine home hospice care. Transfusions are administered by trained transfusion nurses. Standard hospice care is provided by an interdisciplinary team of non-transfusion nurse case managers, hospice aides, social workers, and chaplains.

Study Details

This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice (i.e, HEME-Hospice) compared to regular standard of care improves quality of life, mood, and end-of-life health care utilization for patients with hematologic malignancies.

Key Dates

Start date
Sep 10, 2025
Status verified
Sep 2025
Primary completion
May 31, 2029
Completion
May 31, 2029

Study Design

Enrollment
700 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: Arm 1: Access to home blood transfusions while enrolled in hospice (HEME-Hospice care)
    Participants assigned to access to HEME-Hospice care who enroll in hospice will have at least once weekly assessment of symptoms of anemia and thrombocytopenia by the study team and will receive transfusions at home as indicated. Individualized care appointments with hospice care team providers, and frequency of visits are determined by individual participant need.
  • No Intervention: Arm 2: Usual Care
    Participants assigned to usual care will receive standard oncology care delivered by the hematologic oncologists. Participants will have access to regular/standard hospice care if they elect to enroll in hospice.

Primary Outcome Measure

Hospice Enrollment Rate [ Time Frame: 6 months ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Brigham and Women's HospitalBostonMassachusetts02215
Oreofe Odejide, MD, MPH
[email protected]
617-632-6864
Oreofe Odejide, MD, MPH (PRINCIPAL_INVESTIGATOR)
Dana-Farber Cancer InstituteBostonMassachusetts02215
Oreofe Odejide, MD, MPH
[email protected]
617-632-6864
Oreofe O. Odejide, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By condition
Leukemia (other)Multiple myeloma
By specialty
OncologyBlood cancer
By research site
Brigham and Women's Hospital· Boston, MADana-Farber Cancer Institute· Boston, MA

Related Studies